|Day Low/High||29.58 / 30.69|
|52 Wk Low/High||28.72 / 300.00|
Tilray signs a $3.3 million initial supply agreement with a medical cannabis company in Germany.
Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced it has entered into an agreement with Cannamedical Pharma GmbH ("Cannamedical") through its wholly-owned subsidiary Tilray...
It's tough to find when a stock has hit the floor, so let's look at three that fell on earnings and could be poised to rise.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BCRH, DGSE Downgrades: ARLP, CIT, CSLT, ERIC, FTI, LE, NTZ, PICO Initiations: AFIN, BRY, BV, CCB, MYFW, SAGE, TLRY, XERS Read on to get TheStreet Quant Ratings' detailed report:
Canopy Growth reports a quarterly loss of C$1.28 billion.
Canopy Growth could be heading for new lows if longtime support falters. Here's where it's at.
Stocks finished sharply down Wednesday as weak economic data from China, GDP contraction in Germany, and the first inverted U.S. yield curve in more than 12 years stoked fears of a global recession.
Tilray sinks and the entire cannabis sector tumbles.
Analysts at Piper Jaffray believe that while Tilray will face some near-term headwinds it is still well-positioned to be the big winner in the cannabis space.
It's Wednesday, August 14, here's three big stories investors should be watching.
U.S. stock futures decline a day after the U.S. said it would hold off on levying tariffs on Chinese imports, including consumer products such as cellphones, laptops and toys; Cisco and Macy's report earnings; CBS and Viacom merge to form a $30 billion media giant; Tilray sinks after posting a wider-than-expected quarterly loss.
Jim Cramer's tackling the U.S.-China trade war and his thoughts on the tariffs being pushed back to December 15.
The Canadian cannabis company beat analysts' revenue expectation. Net selling price dropped.
Tilray, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today reported financial results for the second quarter ended June 30, 2019.
A host of other cannabis-related stocks has sprouted up that appear better for investing.
After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.
Jim Cramer weighs in on Tilray and why he's looking at other cannabis stocks.
The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Jim Cramer tackles when investors should be getting into gold, whether or not now is the time to sell and what he thinks of the cannabis industry.
There has been some recent consolidation and accumulation in the cannabis stock that could be setting the stage for an upside move.
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
U.S. stock futures fall as unrest in Hong Kong and the ongoing trade tensions between the U.S and China make for jittery investors; Oregon is the 16th state to join a lawsuit blocking the merger of T-Mobile US and Sprint; Verizon reaches deal to sell blogging website Tumblr.
Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has received approval from the U.
Tilray, Inc. ("Tilray" or "the Company") (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda.
ACB stock rallied after the firm says it expects to generate C$100 million to C$107 million in revenue for the three months ended June 30.
The shares slumped amid concern about another Canadian cannabis company's regulatory issues.
Jim Cramer's keeping a close eye on Beyond Meat.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.